Probability of blindness from glaucoma nearly halved since 1980

Article

The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study recently published in Ophthalmology.

San Francisco, CA- The probability of blindness due to glaucoma has decreased by nearly half since 1980, according to a study recently published in Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease but caution that a significant proportion of patients still progress to blindness. 

Significant changes in diagnostic criteria, new therapies and tools, as well as improvements in glaucoma management techniques, have benefited individual patients; however, their effect on the rates of visual impairment on a population level has remained unclear. This study, conducted by a team based at the Mayo Clinic, was the first to assess long-term changes in the risk of progression to blindness and the population incidence of glaucoma-related blindness. By identifying epidemiologic trends in glaucoma, the researchers hope to gain insight into best practices for the distribution of health and medical resources, as well as management approaches for entire populations.

The researchers reviewed every incident case (857 cases total) of open-angle glaucoma (OAG) diagnosed from 1965 to 2009 in Olmsted County, MN. They found that the 20-year probability and the population incidence of blindness due to OAG in at least one eye had decreased from 25.8% for subjects diagnosed between 1965 and 1980 to 13.5% for those diagnosed between 1981 and 2000. The population incidence of blindness within 10 years of diagnosis also decreased from 8.7 per 100,000 to 5.5 per 100,000 for those groups, respectively. Yet, 15% of the patients diagnosed in the more recent timeframe still progressed to blindness.

"Despite this good news, the rate at which people continue to go blind due to OAG is still unacceptably high. This is likely due to late diagnosis and our incomplete understanding of glaucoma, so it is critical that research into this devastating disease continues, and all eye care providers be vigilant in looking for early signs of glaucoma during routine exams,” says Arthur J. Sit, MD, associate professor of ophthalmology at the Mayo Clinic College of Medicine and lead researcher for the study.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
© 2025 MJH Life Sciences

All rights reserved.